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WTXa b s t r a c t
Wilms tumor (WT) is a genetically heterogeneous childhood kidney tumor. Several genetic muta-
tions have been identiﬁed in WT patients, including inactivation of WTX, somatic stabilizing
CTNNB1, and p53 mutations. However, the molecular mechanisms in tumorigenesis remain largely
unexplored. Stat3 is a transcription factor that can promote oncogenesis. Stat3 activation is com-
monly viewed as crucial for multiple tumor proliferation and metastasis. We show that Stat3 is
highly activated in Wilms tumor tissues compared to those in adjacent tissues. IL-6 treatment or
transfection of a constitutively activated Stat3 in G401 cells promotes cell proliferation. At the
molecular level, we further elucidate that Stat3 inhibits WTX expression through up-regulation of
microRNA-370. Our results suggest that Stat3/miR-370/WTX regulatory axis might be a critical
mechanism in Wilms tumor cells.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Wilms tumor is a type of kidney cancer and affects very young
children [1]. Although a number of Wilms tumors have been col-
lected through international trials, the mechanisms remain chal-
lenging to determine [2]. Extensive research has identiﬁed
somatic mutations at several loci in Wilms tumorigenesis, includ-
ing WT1, CTNNB1, WTX and TP53 [2–4].
WTX has been characterized as a key tumor suppressor in
Wilms tumor [5]. Inactivation of WT1 is the most frequent genetic
event in sporadic Wims tumor, reported in up to 30% of cases [5].
Protein interaction studies have suggested that WTX associates
with the APC complex and might negatively regulate b-catenin sta-
bility [6,7]. Besides, it could modulate the transcriptional activity
of WT1, the ﬁrst Wilms tumor suppressor that encodes a zinc ﬁn-
ger transcriptional regulator of cellular differentiation program [8].
Moreover, recent studies have also suggested a positive effect on
p53 signaling through enhancing CBP/P300-mediated acetylation
of p53 at Lysine 382 [9]. Therefore, WTX may regulate Wilms tu-
mor initiation and progression through multiple mechanisms.
However, the molecular determinants of WTX expression remain
largely unexplored.Multiple lines of evidence suggest that aberrant Stat3 signaling
play a central role in the initiation, development and progression of
many human tumors [10,11]. Some of pro-inﬂammatory cytokines
and growth factors secreted by cancer cells or inﬂammatory cells
are activators of Stat3 [12]. For many cancers, elevated levels of
activated Stat3 have been associated with a poor prognosis [13–
15]. In addition to mediating tumor cell proliferation and survival
in a tumor cell-autonomous manner, Stat3 signaling is also crucial
for inﬂammatory cell-mediated transformation and tumor pro-
gression [16,17]. Therefore, inhibiting the Stat3 signaling pathway
is implicated as a promising therapeutic target for developing anti-
cancer drugs.
Here, we report a functional role of Stat3 in Wilms tumor pro-
liferation, initially identiﬁed by the observation of activation in
Wilms tumor tissues. At the molecular level, Stat3 promotes cell
proliferation through up-regulation of microRNA-370, which di-
rectly targets WTX expression. Together, our results suggest a role
of Stat3 in the regulation of WTX and Wilms tumor growth.
2. Material and methods
2.1. Tissue samples
16 Primary Wilms tumor tissues and adjacent tissues were
collected from either therapeutic surgery or endoscopy at our
Fig. 1. Activation of Stat3 promotes Wilms tumor proliferation (A) Western Blot analysis of phosphorylated Stat3 (p-Stat3) expression in Wilms tumor and adjacent normal
tissues. Total Stat3 (t-Stat3) and GAPDH were used as a loading control (B–C). The cell viability (B) and cell proliferative potential (C) were determined in G401 cells treated
with control (PBS) or IL-6 (25 ng/ml). (D) Western Blot analysis of Stat3 protein expression in G401 cells transfected with empty vector (EV) or constitutively activated Stat3
(CA-Stat3). (E–F) The cell viability (E) and cell proliferative potential (F) were determined in G401 cells transfected with EV or CA-Stat3. (G) Western Blot analysis of Stat3
protein expression in G401 cells transfected with siRNA oligos targeting GFP or Stat3 (S1, S2). GFP siRNA was used as a negative control. (H–I). The cell viability (H) and cell
proliferative potential (I) were determined in G401 cells transfected with siRNA oligos as indicated.
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approved by Childrens’ Hospital Afﬁliated to Soochow University.
2.2. Reagents and cell culture
IL-6 was purchased fromMerck, China. The following antibodies
were purchased: anti-STAT3 (Cell Signaling), anti-WTX (Abcam),
anti-p21Cip1 (Santa Cruz), anti-Cyclin D1 (Cell Signaling), anti-acet-
ylated Histone H3 and H4 (Abcam), anti-GAPDH (Santa Cruz). G401
cell lines were obtained from American Type Culture Collection
(ATCC) cultured in RPMI 1640 medium (Gibco), supplemented
with 10% fetal calf serum, 100 IU/ml penicillin and 100 mg/ml
streptomycin.
2.3. siRNA oligos
siRNA oligos targeting GFP or Stat3 were designed and synthe-
sized by GenePharm (Shanghai, China).
2.4. RNA extraction, real-time analysis and Western blotting
Total RNAs were isolated from tissues or cells by TRIzol reagent,
and reverse transcriptions were performed by Takara RNA PCR kit
(Takara, China) following the manufacturer’s instructions. In order
to quantify the transcripts of the interest genes, real-time PCR was
perfomed using a SYBR Green Premix Ex Taq (Takara, Japan) on
Light Cycler 480 (Roche, Switzerland). The primer sequences used
are available upon request. b-Actin and small RNA U6 were used as
a reference to normalize Real-time PCR data for mRNA and microR-
NA analysis respectively. For western blot analysis, tissues and
cells were lysed in radioimmunoprecipitation (RIPA) buffercontaining 50 mM Tris–HCl, 150 mM NaCl, 5 mM MgCl2, 2 mM
EDTA, 1 mM NaF, 1% NP40 and 0.1% SDS.
2.5. Plasmid construction
The miR-370 promoter (850 bp) was ampliﬁed from the human
genomic DNA template and inserted into pGL4 vector (Promega).
Mutant Stat3 binding site was generated using a PCR mutagenesis
kit (Toyobo) with primer (mutation sites underlined) 50-
CCAATGCGTCAATCGACGTACCGCT-30 and a reverse complement
primer. To construct reporter vectors carrying miR-370 target sites,
we synthesized the 30UTR fragments containing the predicted tar-
get sites (Targetscan) for human WTX cDNA, and inserted the frag-
ment of WTX cDNA into the multiple cloning sites in the pMIR-
REPORT™ luciferase miRNA expression reporter vector (Ambion).
2.6. Transient transfections and luciferase assays
All the transient transfections were performed by Lipofectamin
2000 (Invitrogen), according to the manufacturer’s instructions.
For luciferase reporter assay, G401 cells were seeded in 24-well
plates and transfected with the indicated plasmids. Cells were har-
vested 30 hours after transfection. Luciferase activity was mea-
sured using the Dual Luciferase Reporter Assay System (Promega,
USA).
2.7. MTT and BrdU assays
The viability of G401 cells was determined by assaying the
reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-di-phenylte-trazoli-
um bromide (MTT) to formazan. Absorbance was measured at
Fig. 2. Effect of Stat3 activation on the miR-370 expression (A) Real-time PCR
analysis of miR-370 expression in G401 cells treated with control (PBS) or IL-6
(25 ng/ml). (B) miR-370 expression in G401 cells transfected with EV or CA-Stat3.
(C) miR-370 expression in G401 cells transfected with siRNA oligos as indicated. (D)
miR-370 expression in Wilms tumor and adjacent normal tissues.
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tion enzyme-linked immunosorbent assay (BrdU kit; Beyotime)
was used to analyze the incorporation of BrdU during DNA synthe-
sis following the manufacturer’s protocols. All experiments were
performed in triplicate.Fig. 3. Stat3 regulates miR-370 expression at the transcriptional level (A) Relative lucifer
370 promoters and empty vector (EV) or CA-Stat3. (B) Quantitative real-time PCR analysi
prepared from G401 cells treated with PBS or IL-6 (25 ng/ml). (C) ChIP assays with the ind
Ac-H3: Acetylated Histone 3; Ac-H4: Acetylated Histone 4.2.8. ChIP assays
A chromatin immunoprecipitation (ChIP) assay kit was used
(Upstate, USA). In brief, G401 cells were ﬁxed with formaldehyde.
DNA was sheared to fragments at 200–1000 bp using sonications.
The chromatin were incubated and precipitated with antibodies
against the indicated antibodies or IgG (Santa Cruz, USA).
2.9. Statistical analysis
Values were shown as mean ± S.E.M. The two-tailed Student’s t-
test was used to evaluate signiﬁcance of the differences between
two groups. The Statistical signiﬁcance is displayed as (⁄P < 0.05),
(⁄⁄P < 0.01) or (⁄⁄⁄P < 0.001).3. Results
3.1. Persistent of stat3 activation is a frequent event in Wilms tumor
tissues
First, we analyzed Stat3 activation in 16 Primary Wilms tumor
tissues and adjacent non-tumor tissues by way of western blot.
As shown in Fig. 1A and Supplementary Fig. 1, we observed the
heavy presence of phosphorylated Stat3 in tumor tissues, which
indicates the persistent activation of Stat3 in these malignant
areas.
To address the functions of Stat3 in Wilms tumors, G401 cells
were exposed to IL-6, a classical Stat3 agonist, and assessed using
an MTT assay. As a result, we observed that the growth rate of cells
was dramatically increased upon IL-6 treatment (Fig. 1B). The ef-
fect of IL-6 was further conﬁrmed by measuring the BrdU incorpo-
ration in G401 cells (Fig. 1C). To further exclude the nonspeciﬁcase activity of G401 cells co-transfected with wild-type (WT) or mutant (Mut) miR-
s of ChIP assays showing Stat3 binding to the S1pr1 promoter. The chromatins were
icated antibodies in G401 cells transfected with siRNA oligos targeting GFP or Stat3.
Fig. 4. miR-370 promotes the proliferation ofWilms tumor cells. (A–B) The cell viability (A) and cell proliferative potential (B) were determined in G401 cells transfected with
negative control (NC) or miR-370 mimics. (C) Western blotting analysis indicating decreased expression of p21Cip1 and increased expression of cyclin D1 in G401 cells
transfected with negative control (NC) or miR-370. (D–E) The cell viability (D) and cell proliferative potential (E) were determined in G401 cells transfected with negative
control (NC) or miR-370 inhibitor. (F) Western blotting analysis indicating decreased expression of p21Cip1 and increased expression of cyclin D1 in G401 cells transfected
with negative control (NC) or miR-370 inhibitor.
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mid containing constitutively activated Stat3 (CA-Stat3) [17]. Sim-
ilarly, the growth rates were also increased in cells ectopically
expressing CA-Stat3, compared to empty vector-transfected cells
(Fig. 1D–F).
As described above, Stat3 plays a positive role in the prolifera-
tion of Wilms tumor cells. However, it remained unexplored
whether inhibiting Stat3 would reduce cell proliferation. As ex-
pected, inhibition of Stat3 using two small interfering (si) RNA oli-
gos signiﬁcantly reduced the growth of G401 cells, as measured by
MTT and BrdU assays (Fig. 1G–I). Moreover, Stat3 deﬁciency dra-
matically abrogated the roles of IL-6 in G401 cells (Supplementary
Fig. 2A and B). Together, these results demonstrate that persistent
activation of Stat3 is crucial and essential for the proliferation of
Wilms tumor cells.
3.2. Regulation of miR-370 by Stat3 activation
At the molecular level, Stat3 modulates the transcription of a
variety of genes involved in the regulation of critical functions,
including cell differentiation, proliferation, apoptosis, angiogene-
sis, metastasis and immune responses [18]. However, whether
microRNA involved in the roles of Stat3 remain poorly understood.
Here, to explore the speciﬁc target of Stat3 in Wilms tumor cells,
microRNA (miR) arrays prepared from G401 cells were performed.
As suggested by our array data, miR-370 was dramatically elevated
in G401 cells treated with IL-6 (data not shown). Besides, our real-
time PCR analysis also conﬁrmed the up-regulation of miR-370 by
IL-6 treatment or transfection of CA-Stat3 (Fig. 2A and B). Consis-
tently, targeted knockdown of Stat3 also reduced microRNA-370
expression (Fig. 2C), suggesting that Stat3 activation could up-reg-
ulate miR-370 abundance. Moreover, the expression level of miR-
370 was also elevated in Wilms tumor tissues, compared withadjacent non-tumor tissues (Fig. 2D), further supporting the notion
that Stat3 is an upstream signaling for the induction of miR-370.
3.3. STAT3 transcriptionally activates microRNA-370 expression
We next determined whether STAT3 might be a transcriptional
activator of miR-370. We transfected G401 cells with a reporter
vector encoding luciferase under control of the miR-370 promoter
(PGL4-370.WT). Concurrent expression of CA-Stat3 with the micr-
oRNA-370 reporter construct increased miR-370 promoter activity
(Fig. 3A), which was abrogated by mutation of the Stat3 DNA-bind-
ing site (PGL4-370.Mut) in the miR-370 promoter (Fig. 3A). We
next carried out chromatin immunoprecipitation (ChIP) assays to
assess whether Stat3 directly binds the miR-370 promoter. Indeed,
Stat3 protein bound the miR-370 promoter was signiﬁcantly in-
creased in G401 cells treated with IL-6 (Fig. 3B). Stat3 knockdown
by siRNA abrogated Stat3 binding to the miR-370 promoter and re-
duced association of acetylated histone H3, H4 with the promoter,
suggesting the requirement of Stat3 for miR-370 promoter activity
(Fig. 3C).
3.4. miR-370 regulates proliferation and enhances tumorigenicity
In order to investigate the roles of miR-370 in Wilms tumors,
we transfected a has-miR-370 mimic into G401 cells and measured
cell proliferation. Using MTT and BrdU assays, we observed that the
growth rate of miR-370 overexpressing cells was dramatically in-
creased, compared to negative control (NC)-transfected cells
(Fig. 4A and B). As miR-370 promoted cell proliferation, we ex-
plored the effect of miR-370 on expression of the genes which reg-
ulate cell cycle progression, including CDK inhibitor p21Cip1,
p27Cip1 and the CDK regulator cyclin D1. Using western blot
analysis, we observed that p21Cip1 and p27Cip1 proteins were
Fig. 5. MiR-370 down-regulates WTX by directly targeting the WTX 30-UTR. (A) Relative luciferase activity of wild-type (WT) or mutant (Mut) WTX 30-UTR in G401 cells
transfected with negative control (NC) or miR-370. (B–C) Real-time PCR (B) and Western blot (C) analysis of WTX expression levels in G401 cells transfected with negative
control (NC) or miR-370. (D–E) Real-time PCR (D) and Western blot (E) analysis of WTX expression levels in G401 cells transfected with negative control (NC) or miR-370
inhibitor.
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370-transfected cells, compared to NC-transfected cells (Fig. 4C).
In addition, inhibition of miR-370 markedly reduced the growth
of G401 cells, compared to NC-transfected cells (Fig. 4D and E).
Consistently, the protein levels of p21Cip1, p27Cip1 and cyclin D1
were also altered correspondingly (Fig. 4F). Taken together, these
results support a role for miR-370 in Wilms tumor in enhancing
cell proliferation.
3.5. miR-370 directly targets WTX in Wilms tumor cells
To predict the possible target gene of miR-370, we carried out a
computational analysis on Targetscan (http://www.targetscan.org/
), which suggested that miR-370 may directly target the 30-UTR of
WTX. To conﬁrm WTX as the target gene of miR-370, we engi-
neered the fragment of WTX gene containing the binding sites
for miR-370 into luciferase reporter vector and carried out lucifer-
ase reporter activity assay. As illustrated in Fig. 5A, transfection of
miR-370 caused a substantial reduction of luciferase activity on the
luciferase expression constructs carrying the target fragment. Be-
sides, the repressive effect of miR-370 on the WTX 30-UTR was
abrogated by point mutations in the miR-370-binding seed region
of the WTX 30-UTR (Fig. 5A).
Moreover, ectopic expression of miR-370 decreased the mRNA
and protein expression levels of WTX in G401 cells (Fig. 5B and
C), while transfection of miR-370 inhibitor up-regulated WTX
mRNA and protein abundance (Fig. 5D and E). Together, our results
conﬁrm that WTX gene is a target of miR-370.
4. Discussion
In this study, we demonstrated that Stat3 is highly activated in
Wilms tumor tissues, compared to adjacent normal tissues. At the
molecular level, we found that miR-370 was a transcriptionaltarget of Stat3. Overexpression of miR-370 promoted cell prolifer-
ation, which correlated with down-regulation of p27Cip1 and up-
regulation of Cyclin D1. In contrast, inhibition of miR-370 reduced
tumor cell proliferation, up-regulated p27Cip1 and down-regulated
Cyclin D1. Furthermore, we showed that miR-370 could directly
target the WTX 30-UTR, suggesting that WTX is regulated by miR-
370 in Wilms tumor cells. Collectively, our ﬁndings indicate that
activation of Stat3 may promote the initiation and progression of
Wilms tumor through up-regulation of miR-370 and subsequently
reduction of WTX.
MicroRNAs are small non-coding RNAs regulating gene expres-
sion at the post-transcriptional and/or translational levels [19].
MicroRNAs play important roles in various biological processes,
including development, cell proliferation, differentiation, metabo-
lisms [19]. Recent studies have proved that expression of many
MicroRNAs is changed in many types of cancer, suggesting MicroR-
NAs exert key roles that lead to carcinogenesis [20–22]. It has been
documented that miR-370 plays important roles in several kinds of
cancer cells. For example, up-regulation of miR-370 promoted the
entry of DU145 and LNCaP prostate cancer cells into the G1/S cell
cycle transition [23]. Besides, Overexpression of miR-370 contrib-
uted to the progression of gastric carcinoma through targeting
transforming growth factor-b receptor II (TGFb-RII) gene [24].
Therefore, our current study adds an additional role and mecha-
nism for the miR-370 in tumor cells. Besides, it was shown that
miR-562 expression was reduced in Wilms tumor and may con-
tribute to tumorigenesis while miR-483-3p was overexpressed in
Wilms tumors [25,26]. Therefore, regulation of microRNAs may
provide a novel insight into the pathogenic development of Wilms
tumors.
In summary, the key ﬁnding of the current study is that Stat3
activation could increase the proliferation of Wilm tumor cells, at
least in part, through up-regulation of miR-370, which in turn
down-regulates the tumor suppressor gene WTX. Understanding
644 X. Cao et al. / FEBS Letters 587 (2013) 639–644the precise roles played by Stat3/microRNA-370/WTX regulatory
axis will not only advance our knowledge of Wilms tumor biology,
but also will help determine if Stat3 and miR-370 has potential as a
novel therapeutic target for the treatment of Wilms tumor.
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